Quibim, a Valencia-based HealthTech firm innovating using imaging biomarkers for precision medication, introduced right this moment the shut of its €47.9 million Collection A financing so as set up US presence.
The financing was led by Asabys (by way of its fund Sabadell Asabys II) and Buenavista Fairness Companions (by way of the BHG I fund, created in partnership with Columbus Enterprise Companions), and joined by GoHub Ventures and UI Investissement as new buyers. It was additionally joined by present buyers, Amadeus Capital Companions, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund’s early development fund), Tony Fadell’s Construct Collective, and particular person investor Dr. Jonathan Milner, founding father of Abcam plc.
“Quibim’s mission is to show imaging right into a catalyst for precision well being, and we’re deeply grateful to each our new and present buyers for his or her help,” mentioned Dr Ángel Alberich-Bayarri, CEO and Co-founder of Quibim. “Our international enlargement into the U.S. is a essential milestone as we work with pharmaceutical leaders and healthcare suppliers to unlock the facility of imaging to revolutionise diagnostics and enhance affected person outcomes.”
Based in 2012 by Dr Ángel Alberich-Bayarri and Luis Martí Bonmatí, Quibim is devoted to the mission of unlocking an entire, non-invasive understanding of each tissue level within the human physique, at any second in time. To realize this, the corporate develops foundational AI fashions utilized to imaging that extract actionable insights from MRI, CT, and PET scans. These insights allow exact characterisation of phenotypes and prediction of outcomes in areas equivalent to oncology, immunology, neurology and metabolic issues.
Quibim says that is the pathway towards reaching human digital twins, dynamic fashions that not solely replicate and permit well being monitoring but additionally improve affected person stratification, enhance the success charges of drug growth packages, and allow therapy testing earlier than utility.
At present, the corporate is constructing digital twins on the organ and lesion stage, exemplified by options like QP-Mind, QP-Prostate, and QP-Liver.
Nonetheless, as the quantity of whole-body scans and associated imaging information continues to develop within the coming years, Quibim goals for his or her fashions to ultimately analyse your complete physique.
With over 170 installations worldwide, together with in Mass Basic Brigham and Stanford, and regulatory clearances throughout the US, EU, UK, Quibim’s know-how appears to bridgethe hole between analysis, medical apply, and drug growth.
Final yr, Philips introduced a world partnership with Quibim to combine its AI fashions into MR scanners, whereas the corporate additionally secured strategic alliances with main biopharma giants equivalent to Merck KGaA and Novartis.
“Asabys is thrilled to help Quibim in remodeling the imaging diagnostics house,” mentioned Guillem Masferrer, Accomplice at Asabys Companions. “Their capability to mix AI with imaging biomarker discovery addresses essential unmet wants in oncology, neurology, and past. We’re assured that Quibim’s revolutionary options could have a profound affect on international healthcare.”
Quibim’s product portfolio contains:
- QP-Prostate®: the corporate’s flagship product is designed to reinforce prostate most cancers detection by way of an industry-leading AI-powered lesion detection.
- QP-Mind®: AI-based early-stage neurological illness quantification software program for quantification of early mind atrophy and lesions.
- QP-Liver®: automated AI device for MR analysis of diffuse liver ailments by way of correct quantification of tissue fats and iron ranges.
- QP-Insights®: A platform to handle, retailer and analyse multi-omics information in medical trials and real-world information research. Based on Quibim, QP-Insights is the platform managing the most important imaging datasets on the planet, accounting for greater than 100 million medical pictures.
With the collection A financing, Quibim will set up a powerful U.S. presence, constructing on its success in Europe, by way of strategic collaborations with hospitals and pharmaceutical corporations.
“Quibim’s know-how exemplifies the following wave of precision medication,” mentioned José Mesa, Accomplice at Columbus and Buenavista’s consultant on the Board. “Their spectacular observe file with international pharmaceutical partnerships, together with partnerships with corporations equivalent to Merck KGaA and Philips, exemplify Quibim’s function in remodeling imaging information into worthwhile predictions for medical trials and therapy planning. We count on that as Quibim develops its pipeline of companion diagnostic instruments, we’ll see great momentum for its know-how and merchandise.”
“The foundational analysis carried out by Quibim’s group has not solely knowledgeable {industry} requirements, but additionally led to the corporate pioneering an strategy to combining radiomics and deep studying that’s now a regular of its personal,” mentioned Pierre Socha, Accomplice at Amadeus Capital Companions. “This platform strategy was novel on the time of our first funding and proved to be the fitting technique for fast scale-up.”
